Plasmodium vivax treatment: Brazil approves single-dose tafenoquine, or Kozenis for radical cure
by Press Release from Outbreak News Today on (#4TEFW)
GSK Brazil and Medicines for Malaria Venture (MMV) today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted Marketing Authorization Approval, under Priority Review, for single-dose tafenoquine (brand name Kozenis) for the radical cure (prevention of relapse) of Plasmodium vivax (P. vivax) malaria in patients aged 16 years and older who are receiving chloroquine for acute P. ["]
The post Plasmodium vivax treatment: Brazil approves single-dose tafenoquine, or Kozenis for radical cure appeared first on Outbreak News Today.